热门资讯> 正文
AC Immune更新了帕金森病候选人中期试验的数据
2025-04-02 18:52
- AC Immune (NASDAQ:ACIU) added ~22% in the premarket on Wednesday after the Swiss biotech shared additional interim results from a mid-stage trial for ACI-7104.056, its experimental therapy targeted at the neurodegenerative disorder Parkinson’s disease.
- Citing immunogenicity data from its Phase 2 VacSYn clinical trial, AC Immune (NASDAQ:ACIU) said ACI-7104.056 led to a high level of antibodies against alpha-synuclein, which is believed to play a major role in causing PD.
- According to the company, after six months of treatment in the study for patients with early PD, the level of anti-a-syn antibodies seen following four immunizations of ACI-7104.056 was over 20-fold higher than that for placebo.
- The experimental therapy was well tolerated without any safety issues so far, AC Immune (NASDAQ:ACIU) added, noting its plans to share additional updates later this year.
More on AC Immune
- AC Immune: Leader In Dementia Therapies, A Space Littered With Failures
- Seeking Alpha’s Quant Rating on AC Immune
- Historical earnings data for AC Immune
- Financial information for AC Immune
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
